Deutsche Bank Reports on Gilead Sciences

Deutsche Bank commented on Gilead Sciences GILD in a report released today. In the report, Deutsche Bank was positive in its assessment of the company. Deutsche Bank writes, "Analysis of IMS weekly scrips for the 6th week of Q2:11 indicates that GILD's HIV franchise is tracking slightly below street consensus estimates. Overall scrip trends suggest $14.4.M lower HIV sales vs. consensus. Caveat: These trends are only based on 6 weeks of IMS data in Q2 (14 weeks total)." Deutsche Bank currently has a Buy rating on Gilead Sciences and a price target of $45. Shares of Gilead Sciences closed at $40.98 on Friday, down $0.06 from the opening bell.